Physician profile
Summer Liew
NPI 1205354602
$15,742.28
in general payments reported to CMS, 2019-2025
26 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,214 · 2022: $3,907 · 2023: $4,117 · 2024: $4,255 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,336 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,335.89 |
| Education | $285.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,260.51 | 2021-2025 | Rinvoq, Skyrizi |
| Genzyme Corporation | $1,691.66 | 2021-2025 | |
| Janssen Biotech, INC. | $1,597.65 | 2023-2025 | Tremfya, Simponi Aria, Stelara |
| Regeneron Healthcare Solutions, INC. | $1,051.13 | 2021-2025 | Dupixent |
| Epi Health, LLC | $1,050.01 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $1,013.26 | 2022-2025 | Ilumya, Winlevi |
| Ucb, INC. | $859.03 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $617.32 | 2021-2025 | |
| Lilly USA, LLC | $614.89 | 2021-2025 | Taltz, Olumiant, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $569.67 | 2022-2024 | Sotyktu |
| Dermavant Sciences, INC. | $551.13 | 2023-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $517.91 | 2023-2025 | Tremfya |
| Galderma Laboratories, L.P. | $506.85 | 2021-2025 | Aklief, Nemluvio |
| Amgen INC. | $371.10 | 2021-2024 | Otezla |
| Arcutis Biotherapeutics, INC. | $357.27 | 2023-2024 | Zoryve |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $348.89 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $232.16 | 2022-2023 | |
| Leo Pharma INC. | $89.42 | 2023-2025 | Adbry |
| Allergan, INC. | $84.41 | 2022 | |
| Almirall LLC | $83.27 | 2021-2022 | |
| Genentech USA, INC. | $72.73 | 2022 | |
| Kyowa Kirin, INC. | $65.57 | 2023 | Poteligeo |
| Sanofi-Aventis U.S. LLC | $51.98 | 2022 | |
| Mayne Pharma Commercial LLC | $47.68 | 2021-2025 | |
| Fresenius Kabi USA, LLC | $19.06 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $17.72 | 2025 | Imfinzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Liew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.